On December 1, 2021, the Beijing Municipal Bureau of Economy and Information issued an announcement on the seventh batch of "specialized, refined, and new" small and medium-sized enterprises in 2021. The announcement announced that Beijing Amet Medical Equipment Co., Ltd. was recognized as a "specialized, refined and new" enterprise. This event marks that Amet, as an innovative enterprise, has reached a high level in terms of scientific research strength, technical level and influence, and has been recognized by the competent government departments.

"Specialized, refined and new" refers to the development characteristics of enterprises with specialization, refinement, specialization and novelty. The "specialized, refined and innovative" certification is an important measure implemented by the state to guide small and medium-sized enterprises to take the road of specialization, refinement, specialization, and novelty, enhance independent innovation capabilities and core competitiveness, and continuously improve the quality and level of small and medium-sized enterprises. project.

Beijing Amet is a high-tech company engaged in the research and development of implanted interventional medical devices using self-developed 3D multi-axis precision printing technology. It has a professional, innovative and global talent team composed of experts, professors, doctors and masters. It also has an expert committee composed of well-known academicians, experts and professors at home and abroad. The company has participated in the "Twelfth Five-Year" scientific and technological support plan of the Ministry of Science and Technology, the "Thirteenth Five-Year" key research and development projects of the Ministry of Science and Technology, the Beijing Municipal Science and Technology Commission's strategic and emerging industry cultivation projects, the Beijing Municipal Science and Technology Commission's preclinical and clinical trial projects, The transformation of Zhongguancun's high-precision and advanced achievements and the transformation of Zhongguancun's disruptive technologies and achievements. The company also has an academician expert workstation and a post-doctoral research workstation approved by the state.

Amet's product line covers the fields of implantation and interventional products in coronary, peripheral, intracranial and digestive tract. Its 3D-printed fully degradable coronary drug-eluting stent system AMSorb is undergoing large-scale clinical trials, its 3D-printed fully-degradable peripheral drug-eluting stent system PeriSorb has also been approved by NMPA for clinical trials, and its high-pressure balloon dilatation catheter product, Swordfish Belden, has Obtained NMPA product registration certificate. In the next few years, Amet will have more innovative products enter clinical trials and obtain product registration certificates.